Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: Evidence of glucose metabolism abnormalities

QJM: An International Journal of Medicine

Volumn 101, Issue 1, 2008, Pages 31-40

  Alexandraki, K I ^a   Makras, P ^b   Protogerou, A D ^c   Dimitriou, K ^d   Stathopoulou, A ^d   Papadogias, D S ^d   Voidonikola, P ^c   Piaditis, G ^d   Pittas, A ^e   Papamichael, C M ^c   Grossman, A B ^f   Kaltsas, G ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

^e TUFTS MEDICAL CENTER   (United States)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; GLUCOCORTICOID; GLUCOSE; GROWTH HORMONE; INSULIN; LIPID; MERCAPTOPURINE; METHOTREXATE; VINBLASTINE; VINCRISTINE;

ADENOHYPOPHYSIS; ADULT; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES INSIPIDUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HISTIOCYTOSIS X; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; VASCULAR ENDOTHELIUM;

EID: 38349148647     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm118     Document Type: Article

References (37)

1. Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F. Langerhans-cell histiocytosis in adults. Med Pediatr Oncol 1997; 28:9-14.
2. Dunger DB, Broadbent V, Yeoman E, Seckl JR, Lightman SL, Grant DB, et al. The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. N Engl J Med 1989; 321:1157-62.
3. Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH, et al. Langerhans'-cell histiocytosis (histiocytosis X)-a clonal proliferative disease. N Engl J Med 1994; 331:154-60.
4. de Graaf JH, Tamminga RY, Dam-Meiring A, Kamps WA, Timens W. The presence of cytokines in Langerhans' cell histiocytosis. J Pathol 1996; 180:400-6.
5. Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E. Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: Abundant expression of cytokines relevant to disease and treatment. Blood 1999; 94:4195-201.
6. Malpas JS. Langerhans cell histiocytosis in adults. Hematol Oncol Clin North Am 1998; 12:259-268.
7. Willis B, Ablin A, Weinberg V, Zoger S, Wara WM, Matthay KK. Disease course and late sequelae of Langerhans' cell histiocylosis: 25-year experience at the University of California, San Francisco. J Clin Oncol 1996; 14:2073-82.
8. Grois NG, Favara BE, Mostbeck GH, Prayer D. Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:287-305.
9. Makras P, Samara C, Antoniou M, Zetos A, Papadogias D, Nikolakopoulou Z, et al. Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histilocytosis (LCH). Neuroradiology 2006; 48:37-44.
10. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular difease in hypopituitarism. Lancet 1990; 336:285-8.
11. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141:764-70.
12. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: Old hormones, new targets. Clin Sci 1999; 96:513-23.
13. Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994; 331:468-9.
14. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159:1104-9.
15. Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular enclothelial function. Diabet Med 2003; 20:255-68.
16. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128:262-9.
17. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26 1235-41.
18. Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003; 39:2341-8.
19. Alexandraki K, Protogerou A, Papaioannou TG, Piperi C, Mastorakos G, Lekakis J, et al. Early microvascular and macrovascular dysfunction is not accompanied by structural injury in polycystic ovary syndrome. Hormones 2006; 5:126-36.
20. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83:2694-8.
21. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987; 79:790-800.
22. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85:2402-10.
23. Trochtenberg DS, Dessypris EN. Reversible hepatomegaly and diabetes mellitus in an adult with diseminated histiocytosis X. Am J Med Sci 1990; 299:179-84.
24. Ben Ghorbel I, Houman MH, B'chir S, Chamakhi S, Miled M A disseminated form of Langerhans histiocytosis associated with diabetes insipidus and diabetes mellitus. Rev Med Interne 2001; 22:469-74.
25. Thai AC, Sng I, Suri R, Cheah JS. Disseminated histiocytosis X with diabetes insipidus and diabetes mellitus in an adult female (histiocytosis with DI and DM). Ann Acad Med Singapore 1988; 17 294-8.
26. Rowntree LG, Poppiti RJ. Diabetes insipidus, diabetes mellitus and insulin resistance with histiocytosis. JAMA 1954; 156:310-2.
27. Behrens RJ, Levi AW, Westra WH, Dutta D, Copper DS. Langerhans cell histiocytosis of the thyroid: A report of two cases and review of the literature. Thyroid 2001; 11:697-705.
28. Hurley PJ, Hitchcock GC, Wilson JD. Histiocytosis X and double diabetes. Austr Ann Med 1967; 16:250-4.
29. Riggio O, Merli M, Cangiano C, Capocaccia R, Cascino A, Lala A, et al Glucose intolerance in liver cirrhosis. Metabolism 1982; 31 627-34.
30. Shankar TP, Solomon SS, Duckworth WC, Himmelstein S, Gray S, Jerkins T, et al. Studies of glucose intolerance in cirrhosis of the liver. J Lab Clin Med 1983; 102:459-69.
31. Greco AV, Rebuzzi AG, Altomonte L, Manna R, Bertoli A, Ghirlanda G. Glucose, insulin and somatostatin infusion for the determination of insulin-resistance in liver cirrhosis. Horm Met Res 1979; 11 547-9.
32. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89:1273-6.
33. Erfurth EM, Hagmar L. Cerebrovascular disease in patients with pituitary tumors. Trends Endocrinol Metab 2005; 16:334-42.
34. Yuen KC, Frystyk J, White DK, Twickler TB, Koppeschaar HP, Harris PE, et al. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol 2005; 63:428-36.
35. Bulow B, Hagmar L, Eskilsson.J, Erfurth EM. Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J Clin Endocrinol Metab 2000; 85:574-84.
36. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al A central role for JNK in obesity and insulin resistance. Nature 2002; 420:333-6.
37. Beckman JA, Goldfine AB, Dunaif A, Gerhard-Herman M, Creager MA. Endothelial function varies according to insulin resistance disease type. Diabetes Care 2007; 30:1226-32.